Sebastian E. Carrasco
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Purpose. Triple negative breast cancer (TNBC) is highly aggressive and heterogeneous with high rates of disease recurrence and poor treatment outcomes. The extra domain A of fibronectin (EDA-FN) is an extracellular matrix protein with high abundance in TNBC stroma and limited expression in healthy human tissues. Theranostic approaches have demonstrated improved patient outcomes by utilizing identical targeting vectors for patient stratification by targeted positron emission tomography imaging and radioligand therapy, however no targeted radiopharmaceuticals are currently approved for TNBC. Experimental Design. [89Zr]Zr-DFO-F8 and [177Lu]Lu-CHX-A’’-DTPA-F8 were synthesized and characterized in vitro and in vivo for comparability in binding and biodistribution. Dosimetry estimation identified optimal dosing parameters for therapeutic benefit with limited off-target toxicities. [177Lu]Lu-CHX-A’’-DTPA-F8 was assessed as a therapeutic against two triple negative breast cancer xenograft mouse models. Weekly health and hematological assessment with terminal serum chemistry and histopathology analysis was performed to evaluate toxicities. Results. [89Zr]Zr-DFO-F8 and [177Lu]Lu-CHX-A’’-DTPA-F8 exhibited similar in vitro characteristics, and similar tumor accumulation in two different xenografted mouse models of triple negative breast cancer. [177Lu]Lu-CHX-A’’-DTPA-F8 treatment significantly prolonged survival in both mouse models with only transient myelosuppression and off-target myelotoxicity only in Rag2-/- mice receiving the highest dose of radiolabeled F8 antibody, as determined by blood measurements and terminal histopathology. Conclusion. The 89Zr/177Lu theranostic nuclide coupling successfully identified triple negative breast cancer xenografts, and significantly extended survival of xenografted mice.
Year:
2026
Year:
2026
Purpose: Trophoblast cell surface antigen-2 (Trop-2) is a membrane-bound antigen associated with cancer invasiveness and poorer patient outcomes. Delivery of therapeutics via Trop-2 targeting antibody-drug conjugates has proven to be a viable and FDA-approved model. However, in the clinic, antibody-drug-conjugate dosing is not based on Trop-2 positivity or expression, leading to potential adverse effects if the antigen membrane level on cancer cells is insufficient for targeting. The challenge of adequate patient and therapy selection can be overcome by leveraging the theranostic approach. We previously established a Trop-2.2 antibody for immunoPET imaging allowing us to theoretically select patients with positive Trop-2 lesions. Experimental Design: In this work, the antibody, Trop-2.2, was repurposed for Lutetium-177, Actinium-225, and Lead-212 radiotherapies. We explored the benefits of direct, tandem, pretargeted, and fractionated approaches to radiopharmaceutical dosing. Results: Therapy with the alpha emitter Actinium-225 regressed tumors, with 8/10 mice alive after 150 days. Alternatively, Lead-212, a shorter-lived in vivo alpha generator therapeutic, was found to be more effective when harnessing the pretargeting strategy compared to a directly labeled approach. Our in-house Lead-212 production allowed us to investigate fractionated dosing on a weekly basis. Fractionation resulted in tumor reductions through 12 weeks of therapy with minimal and reversible blood toxicity for the lowest dose. With repeat administrations, we found pathologically significant renal and ovarian toxicity attributable to Lead-212 administration, but an otherwise effective pretargeting method. Conclusions: Here, we provide several direct and pretargeted radiopharmaceutical variants yielding therapeutic benefit for a Trop-2.2 expressing pancreatic cancer model.
Year:
2026
Ferritin, consisting of ferritin heavy chain (FTH1) and light chain (FTL) subunits, is an essential intracellular iron storage protein fundamental for cellular function. However, the source and the biological role of extracellular ferritin (ex-ferritin) are less understood. Recent studies have linked elevated serum ex-ferritin with adverse outcomes in individuals with acute respiratory distress syndrome (ARDS). In this study, we demonstrate that both FTH1 and FTL are significantly enriched in the serum, blood monocytes, and alveolar macrophages (AMs) of individuals with ARDS, a phenomenon we successfully replicate in a murine hyperoxia-induced acute lung injury (HALI) model. We show that FTH1 is consistently upregulated in macrophages during lung injury development, and mice with a targeted deletion of FTH1 in myeloid (LysMcre) or resident lung macrophage (Cd11ccre) populations exhibit attenuated HALI. This reduced injury is linked to macrophage resistance to ferroptotic cell death, ferritinophagy, altered airway inflammatory responses, and lower lung extracellular iron and higher levels of FTL-ex-ferritin. Transplantation of FTL-ex-ferritin-enriched bronchoalveolar lavage fluid to wild-type mice protected against HALI. The ratio of FTL-ex-ferritin to FTH1 in the serum of individuals with ARDS who died was higher than that of those that survived, suggesting that the balance between FTH1 and FTL may play a role in injury modulation. Our findings highlight macrophage ferritin as a key regulator of macrophage survival and the response of the lung to injury, presenting a potentially targetable pathway for ARDS treatment.
Year:
2026
Year:
2025
The murine bacterial pathogen Chlamydia muridarum (Cm) has been used to study human Chlamydia infections in various mouse models. CD4 + T-cells, natural killer cells, and interferon-gamma (IFN-γ)–mediated immunity are important to control experimentally induced Cm infections. Despite its experimental use, natural infection by Cm has not been documented in laboratory mice since the 1940s. In 2022, the authors reported the discovery of natural Cm infections in numerous academic institutional laboratory mouse colonies around the globe. To evaluate the impact of Cm infection in severely immunocompromised mice, 19 NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice were cohoused with Cm shedding, naturally infected immunocompetent mice and/or their soiled bedding for 4 weeks and subsequently euthanized. Clinical disease, characterized by lethargy, dyspnea, and weight loss, was observed in 11/19 NSG mice, and 16/18 NSG mice had neutrophilia. All mice exhibited multifocal to coalescing histiocytic and neutrophilic bronchointerstitial pneumonia (17/19) or bronchiolitis (2/19) with intraepithelial chlamydial inclusions (CIs). Immunofluorescence showed CIs were often associated with bronchiolar epithelium. CIs were frequently detected by immunohistochemistry in tracheal and bronchiolar epithelium (19/19), as well as throughout the small and large intestinal epithelium without lesions (19/19). In a subset of cases, Cm colonized the surface epithelium in the nasopharynx (16/19), nasal cavity (7/19), and middle ear canal (5/19). Endometritis and salpingitis with intraepithelial CI were identified in a single mouse. These findings demonstrate that Cm infection acquired through direct contact or soiled bedding causes significant pulmonary pathology and widespread intestinal colonization in NSG mice.
Year:
2023
Collaborators (10)
Cem Meydan
Assistant Professor
Weill Cornell Medicine
Karla Ballman
Chair / Consultant / Professor of Biostatistics
Mayo Clinic College of Medicine and Science
David Bauer
Assistant Professor
University of Missouri Columbia
Chul-Hee Lee
Cornell University
Suzanne Cloonan
Associate Professor in Respiratory Biochemistry
Weill Cornell Medicine
Edward Schenck
Assistant Professor of Medicine
Cornell University
Divya Bhatia
Assistant Professor of Immunology in Medicine
Weill Cornell Medicine
John Babich
Professor of Radiopharmaceutical Sciences
Joan and Sanford I Weill Medical College of Cornell University
Jason S. Lewis
Weill Cornell Medical College
Christopher Mason
Professor
Weill Cornell Medical College
Make your next move.
Prepare your application
Review drafts before you send them.